AACR21: Eli Lilly blazes new trail for RET inhibitor, ginning up a response in 9 solid tumor types in early data
Eli Lilly was first to market with its RET fusion-inhibitor Retevmo in May, staking its claim in the rare tumor indication. But Roche wasn’t far on its heels with an approval of its own for RET inhibitor Gavreto, and now Lilly is looking to get the leg up on its closest competitor.
Lilly’s Retevmo posted a 47% objective response rate with responses in nine unique RET fusion-positive tumor types, according to early data from the Phase I/II LIBRETTO-001 unveiled Sunday at the virtual AACR meeting.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.